Great interview. Was wondering what might be behind Novos exit from T1D cell therapy.

Ask them to address a letter to someone.

Seems as if there is only one more step needed for an easy injectable functional cure—hypoimmune.

Do people think that is good or bad news. Seems as if cells in a bag don’t work so moving on to cloaking cells and localized immune modulation seems like good news

The budget of NIH was such a small part of the federal budget that cutting it by 45% can’t really be about cost savings. What is motivating Trump. It’s typically something childish and something a compliment can fix

A Dr Melton paper! Very exciting.

What I don’t understand is there have been several studies over the past three years that say Sotyku may prevent T1D and still there is no clinical study in humans to verify it.

Never underestimate the power of the “I gots mine” attitude to cause people to forget that the society in which they live helped to make them the demigods they are

Very bad news but much worse because from recent statements the company has made during investor conferences it seems as if hypoimmune cells are proving very difficult.

I guess sana is coming at the issue from the other side than vertex—trying to prove the hypo ability of cells rather than the ability of manufactured cells to produce insulin—and they decided to use the most stable platform, deceased donor cells, to prove that ability.

U worked on this didn’t u?

Since companies that are investing millions/billions in research are understandably concerned about ROI it seems that universities should be the ones changing their practices to be more like the private sector. If you are a research institution than you need to invest heavily in research.